Skip to content

Study · Animal study (in vivo) · rat · 2015

1 result

Development of a subcutaneous endometriosis rat model.

Pereira FE, Almeida PR, Dias BH, Vasconcelos PR, Guimarães SB, Medeiros Fd

Acta cirurgica brasileira1 Jan 2015Cited by 9 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with experimental endometriosis, triptorelin pamoate significantly reduced weight of the assessed tissue.

    In plain wordsIn rats with endometriosis, triptorelin significantly reduced the weight of the assessed tissue.

    Outcome
    DecreaseWeight reduction
    Study

    ratn: not reported in source

    Wistar rats with subcutaneous endometriosis
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.18 or 0.56 mg/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Weight reduction was also significant in the triptorelin pamoate and the acetylsalicylic acid groups.
    3 context sentences
    Summary · context
    The relative dry and wet weights of the endometrioma were used to evaluate response to the drug.
    Summary · context
    Fifty three-month-old female Wistar rats (Rattus norvergicus) were distributed into one control group and four treatment groups: estradiol (2.5; 5; 10 mg/kg s.c.), medroxyprogesterone acetate (0.5; 2; 5 mg/kg s.c.), triptorelin pamoate (0.18; 0.56 mg/kg s.c.) and acetylsalicylic acid (3 mg/kg per os).
    Summary · context
    Treatments were administered between day 5 and day 14.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.